Data Sheet | October 16, 2025
NULISAqpcr™ BD-pTau217 Assay
Get the Resource
Download NowAs an Alamar Certified Service Provider, Sapient offers the NULISAqpcr™ BD-pTau217 Assay for absolute quantitation of brain-derived pTau217 in plasma.
The NULISA pTau217 assay is a first-of-its-kind offering as the only brain-derived single-plex solution available, and is setting a new benchmark for high-specificity, blood-based measure of the phosphorylated tau 217 (pTau217) isoform originating from the central nervous system.
Tau accumulation in the brain has become a hallmark of many neurodegenerative conditions, with pTau217 emerging as a highly specific biological indicator of Alzheimer’s disease (AD). The challenge is that Tau proteins are distributed throughout the body, secreted not only from the brain but also peripheral organs. When detecting pTau217 in blood for AD, it is therefore critical to distinguish brain-derived isoforms from those originating from other tissues.
Download the data sheet to learn how the NULISAqpcr BD-pTau217 Assay:
- Precisely detects brain-derived pTau217 in plasma, serum, dried blood spots, and CSF using as little as 10 µL of sample.
- Provides absolute quantitation with fg/mL sensitivity and specificity that is unique to the low molecular weight pTau217 isoform originating from the central nervous system.
- Offers a non-invasive alternative to CSF sampling or expensive PET imaging, better enabling large-scale studies and longitudinal clinical trials.
With an ARGO HT system on site, alongside other advanced platforms enabling multi-omics profiling in the same samples, Sapient provides a robust solution to advance your CNS studies with precise pTau217 detection. We also offer broader proteomics and metabolomics screenings along with data analysis services to interpret NULISA data and integrate other omics findings for deeper understanding of AD pathology and CNS treatment response.